6 Best Peptides for ALS (Amyotrophic Lateral Sclerosis)

What to Know Before Choosing a Peptide for ALS

ALS research is a field of genuine scientific urgency and, at the same time, a space where patients often find themselves far ahead of the clinical trial pipeline. The four FDA-approved ALS treatments address the disease through non-peptide mechanisms, and no peptide drug holds FDA approval specifically for ALS as of 2026. That gap is why people searching for options keep landing on peptide research: some compounds have real preclinical data, a few have European or Russian clinical use, and patients are motivated to explore anything with a plausible biological mechanism.

Every compound in this guide earned its place because people use it or are actively discussing using it for ALS. That is the whole test. FDA approval status, evidence depth, and regulatory category are not the filters. A compound available only as a research chemical is just as eligible as one prescribed through a telehealth clinic, and a compound with only community-reported use belongs alongside one with animal trial data, with each one's evidence described as honestly as possible. Leaving out a widely-discussed compound because its literature is thin would make this guide less useful than a forum search.

The entries are numbered because the title needs a spine, not because the numbers mean one compound is better than another for you. The order reflects how prominently each appears in research and documented real-world use for ALS specifically. The right choice for any individual depends on their situation, their neurologist's input, and factors a general guide cannot weigh. That personalized layer is what the MyPeptidePal app handles.

One honest framing before you read further: ALS is a severe, progressive condition, and the peptide field around it is almost entirely preclinical. The compounds below have biological rationales that map onto real ALS pathology, and some have meaningful use patterns in patient communities. None of them should be approached as proven treatments or as substitutes for specialist care.

1. Cerebrolysin: The Most Clinically Familiar Option for Neuronal Support

Cerebrolysin is the compound people in the ALS community most consistently reach for when looking for a peptide with both a real evidence base and actual clinical availability. It is not a single-molecule peptide but a complex biological mixture of low-molecular-weight peptides and free amino acids derived from purified porcine brain proteins. The mixture is designed to mimic the effects of multiple endogenous neurotrophic factors, including BDNF, NGF, GDNF, and NT-3, which are the proteins the nervous system relies on to maintain and repair neurons. In ALS, where motor neurons are progressively dying and neurotrophic signaling is compromised, that is a mechanistically relevant target.

Cerebrolysin has been studied in randomized controlled trials in Europe and parts of Asia, where it holds approval as a pharmaceutical for cognitive and neurological conditions. None of those trials were conducted specifically in ALS populations, and no robust ALS-specific randomized controlled trial has been published. What exists for the ALS context is a combination of extrapolated preclinical neuroprotection data and real-world use at international clinics, particularly in Russia, Eastern Europe, and parts of Asia, where physicians use it for neurological conditions broadly. Some ALS patients obtain it through European or Asian clinics or international pharmacies and administer it by intramuscular or intravenous injection. A smaller number of community users have discussed nebulization as an alternative delivery route, on the theory that it might improve central nervous system bioavailability, though this approach has no published support and the users discussing it acknowledge they are speculating.

The practical picture is this: Cerebrolysin has the most mature evidence base of any peptide people use for ALS, it has real clinical infrastructure around it in some countries, and it sits at the top of this list on prominence of use and the depth of its general neuroprotection literature. That does not make it a proven ALS therapy. It is not FDA-approved for any indication in the United States, its import occupies a legally gray area, and its use for ALS specifically rests on extrapolation rather than direct trial evidence. Patients exploring this route typically do so with the guidance of physicians in countries where it is an approved pharmaceutical.

2. BPC-157: For Nerve Protection and General Regeneration

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide originally derived from a partial sequence found in gastric juice. It is one of the most widely used research peptides in community protocols generally, and it comes up frequently in ALS-specific discussions because of its broad regenerative and neuroprotective properties. People in the ALS community use it hoping it will provide some degree of nerve protection or slow the loss of motor function, and it is among the most accessible peptides through research chemical suppliers and compounding pharmacies in the United States.

The mechanism people point to is BPC-157's ability to promote angiogenesis, the growth of new blood vessels, through VEGF pathway activation, along with general anti-inflammatory effects and signaling through PI3K/Akt and MAPK pathways associated with cell survival. Most of the data behind these mechanisms comes from rodent models studying gut repair, tendon healing, and musculoskeletal recovery. Animal studies support real regenerative effects in those contexts. The translation to motor neuron disease is where the evidence thins considerably: no human clinical trial has been published for BPC-157 in ALS as of 2026, and no ALS-specific animal trial has been conducted on the scale of the musculoskeletal research. What drives its use for ALS is a reasonable hypothesis, a plausible neuroprotective mechanism extrapolated from non-ALS data, combined with broad availability and an active research community.

In community discussions on Reddit and ALS-focused forums, BPC-157 is often mentioned alongside TB-500, the two frequently paired in what users describe as a nerve repair and anti-inflammatory stack. The evidence here is experiential rather than clinical. People report trying it, but there is no community-tracked outcome data that would let anyone assess whether it is doing what people hope. The practical reality also carries real cautions: as a research chemical sourced outside clinical channels, quality control is variable, and the theoretical concern around VEGF-driven growth stimulation is worth raising with a physician before use. BPC-157 holds no FDA approval for any indication and is sold legally in the United States only as a research chemical.

3. Semax: For Neurotrophic Support and Blood-Brain Barrier Access

Semax is a synthetic heptapeptide analog of a fragment of ACTH, the adrenocorticotropic hormone. It was developed in Russia and has been used clinically there and in Ukraine for stroke recovery and cognitive conditions for decades. What makes it relevant to ALS specifically, and what sets it apart from most peptides on this list, is a combination of a well-characterized mechanism that maps directly onto ALS pathology and a confirmed ability to cross the blood-brain barrier, which most peptides cannot reliably do.

The mechanism centers on BDNF, brain-derived neurotrophic factor. ALS involves a significant deficit in neurotrophic signaling, the survival signals that motor neurons depend on. Semax upregulates BDNF expression and activates TrkB, the primary BDNF receptor, which drives neuronal survival pathways. It also reduces reactive neuroinflammation, the secondary wave of damage caused by activated microglia and astrocytes responding to motor neuron death. These are two of the central mechanisms driving ALS progression, which is why Semax appears in mechanistic assessments of ALS peptide candidates with a notably high degree of relevance among the synthetic compounds being considered.

The honest limitation is that none of this has been tested in ALS patients. Semax's clinical record is for stroke and cognitive conditions in Russia and Eastern Europe, and there are no published ALS-specific clinical trials. Community use for ALS is less widespread than for Cerebrolysin or BPC-157, partly because Semax is less familiar to a US-based audience. Among people specifically interested in neurotrophic mechanisms and central nervous system access, however, it comes up consistently in research-oriented ALS discussions as the compound with the most directly relevant preclinical mechanism among the synthetic peptides on this list. In the United States it is available as a research chemical with no FDA approval for any indication.

4. P21 (TLQP-21): A VGF-Derived Neuropeptide Reduced in ALS

P21, also discussed as TLQP-21, is a 21 amino acid neuropeptide derived from VGF, a protein whose expression is driven by nerve growth factor. The reason it appears in ALS discussions is grounded in a specific and meaningful biological observation: levels of VGF-derived peptides, including TLQP-21, are measurably reduced in the cerebrospinal fluid of ALS patients compared to healthy controls. That reduction correlates with disease state, which suggests that loss of VGF-derived neuropeptide signaling may be part of what drives ALS pathology rather than simply a downstream consequence of it.

The mechanism involves Akt and ERK1/2 phosphorylation, two intracellular signaling events that support neuronal survival and reduce excitotoxic damage. In ALS, motor neurons are over-activated and then die partly through excitotoxicity, essentially too much stimulation without adequate protective signaling to counteract it. VGF-derived peptides appear to buffer that process under normal conditions, and their documented reduction in ALS patients is consistent with motor neurons losing one layer of protection. Animal studies and cell culture work support the neuroprotective role, and the logical follow-on question is whether supplementing TLQP-21 could restore some of that protection.

No human clinical trial has been conducted for P21 or TLQP-21 as a therapeutic in ALS as of 2026. The compound is available as a research chemical from peptide suppliers and holds no regulatory approval in any country for this use. Its presence in ALS discussions is more research-oriented than practice-oriented: it is a compound people with ALS and researchers discuss as a biologically interesting candidate, and a smaller number pursue it through research chemical channels. What distinguishes it from many other candidates on this list is a documented biological link to ALS pathology in humans, not just an extrapolated mechanism from unrelated research contexts. That specificity makes it worth including honestly, with the understanding that community use remains limited and the therapeutic evidence base is preclinical.

5. Colivelin: The Hybrid Candidate with ALS-Specific Animal Data

Colivelin is a hybrid neuroprotective peptide that does not occur naturally. It was engineered by combining two smaller peptides: ADNF-9, a nine amino acid fragment of Activity-Dependent Neurotrophic Factor, and Humanin, a mitochondria-associated neuroprotective peptide. The combination was designed to produce dual-mechanism neuroprotection, pairing ADNF-9's neurotrophic activity with Humanin's anti-apoptotic effects. Critically for this list, it has been studied in ALS animal models rather than just general neuroprotection contexts, which gives it a more direct evidentiary connection to ALS than many compounds with broader preclinical support.

In ALS mouse models, Colivelin improved motor performance, increased lifespan compared to untreated controls, and suppressed motor neuron death. These outcomes were measured specifically in animals with ALS-like neurodegeneration, not in general stress or injury models. The mechanistic basis involves activation of the STAT3 pathway and PI3K/Akt signaling, both of which have anti-apoptotic effects that keep stressed neurons alive longer. The Humanin component contributes a layer of mitochondrial protection, which is relevant because mitochondrial dysfunction is a significant feature of ALS pathology in both sporadic and genetic forms of the disease.

What Colivelin does not have is any human data. It has not been tested in clinical trials for ALS or any other condition as of 2026. It is a preclinical-stage compound available through research chemical suppliers with no regulatory approval anywhere. Community use is limited: it is followed in research-focused ALS forums and among people tracking the preclinical literature closely, rather than being broadly self-administered the way BPC-157 or Cerebrolysin are. The ALS-specific animal trial data is what earns it a slot here. The gap between animal models and a disease as complex as human ALS is real and significant, and that gap is stated plainly.

6. GHK-Cu: For Oxidative Stress and the SOD1 Pathway

GHK-Cu is a tripeptide copper complex, glycyl-L-histidyl-L-lysine bound to a copper ion, that occurs naturally in human plasma and declines with age. It is broadly used in skin and tissue repair applications and has independently replicated evidence for wound healing and anti-inflammatory effects across multiple research contexts. Its relevance to ALS is more specific than its general reputation suggests: the mechanism that makes it interesting for ALS maps directly onto one of the disease's best-characterized pathological pathways.

Roughly 20 percent of familial ALS cases involve mutations in the SOD1 gene, which encodes superoxide dismutase 1, an enzyme central to the body's antioxidant defense. Mutant SOD1 drives toxic oxidative stress in motor neurons and contributes to their death. GHK-Cu activates the Nrf2 pathway, which is the master transcription factor governing the body's antioxidant response. Think of Nrf2 as a dial that turns up the production of your cells' own antioxidant enzymes. When GHK-Cu activates it, the result is upregulation of SOD, catalase, and glutathione peroxidase, the enzymes that counteract oxidative damage at the cellular level. There is also a potential link to TDP-43 pathology, the protein aggregation found in over 97 percent of ALS cases: reducing oxidative stress through Nrf2 activation may reduce the stress granule burden that drives TDP-43 mislocalization, though this connection is more theoretical than directly studied.

GHK-Cu's evidence for ALS specifically is preclinical. The Nrf2 mechanism is well-established across broader research, but it has not been tested in ALS clinical trials. In community discussions, at least one user with ALS has reported beginning to explore GHK-Cu for its potential antioxidant effects, though community use is anecdotal and limited. The compound is legally available as a cosmetic ingredient and as a research chemical for injectable use. The SOD1 connection gives it a more specific mechanistic rationale for ALS than many broadly neuroprotective compounds, while the honest position remains that no human ALS data exists.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved specifically for ALS?

No peptide holds FDA approval specifically for ALS as of 2026. The FDA-approved ALS treatments, including riluzole, edaravone, and tofersen for SOD1-linked ALS, work through non-peptide mechanisms. Zilucoplan, a complement-blocking peptide, completed a large and rigorous ALS clinical trial through the HEALEY ALS Platform Trial and did not show significant benefit for disease progression. Every peptide discussed in this guide is used off-label, as a research chemical, or through international clinics operating outside FDA jurisdiction.

Why is the evidence for peptides in ALS almost entirely from animal studies?

ALS clinical trials are exceptionally difficult to run. The disease progresses rapidly, patient populations are relatively small, and the heterogeneity of ALS subtypes makes it hard to isolate a treatment signal. Most peptide candidates have not cleared the funding and safety hurdles required to enter human trials, so researchers rely on ALS mouse models and cell culture work to build a mechanistic case first. Animal models do capture some features of ALS, but they have also produced promising results that failed to replicate in humans, which is why the gap between animal data and clinical evidence is stated plainly for every compound in this guide.

Is it safe to use research peptides for ALS without physician supervision?

Using research-grade peptides without physician involvement carries real risks that go beyond the underlying disease. Unregulated research chemical sources vary significantly in purity, potency, and sterility, and injectable peptides carry infection and dosing risks when used outside clinical settings. In the context of ALS, where patients may already be on complex medication regimens, those risks compound. People exploring these compounds are strongly advised to do so with the involvement of a physician familiar with ALS who can monitor for interactions and adverse effects.

How do people with ALS actually obtain compounds like Cerebrolysin and Semax?

Cerebrolysin is approved and available as a pharmaceutical in Russia, parts of Europe, China, and some other countries. Some patients obtain it through clinics in those regions or through international pharmacies, placing it in a legally gray area for import to the United States. Semax is available as a pharmaceutical in Russia and is sold as a research chemical in the United States. Compounds like BPC-157, P21, and GHK-Cu are available from research chemical suppliers operating legally in the United States as long as the compounds are sold for research purposes rather than for human consumption. Availability does not imply established safety or efficacy, and the quality of research chemical sources varies considerably.

Should someone with ALS speak to their neurologist before trying any of these peptides?

Yes, without qualification. ALS specialists have the clearest picture of how a given patient's disease is progressing, what approved treatments they are on, and what potential interactions or contraindications exist. Some compounds discussed here, particularly those that influence neurotrophic signaling or have growth-stimulating properties, could theoretically interact with disease biology or existing treatments in ways that are not yet understood. A neurologist may not endorse experimental peptide use, but they are the right person to help evaluate the risk-benefit picture for a specific individual.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for ALS (Amyotrophic Lateral Sclerosis) in one place.